secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2026-08-14T11:05:24+00:00
Accession:  0001104659-26-096417
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Q2 2026 net loss $6.5M; TTI-109 to target UC after positive healthy-volunteer data
--------------------------------------------------------------------------------

- Net loss $6.5M vs net income $4.2M in Q2 2025 (prior year had $12.7M non-cash gain); EPS -$0.69.
- TTI-109 healthy-volunteer topline confirms prodrug design, improved tolerability, and immune-cell reductions.
- Selected ulcerative colitis (UC) as first TTI-109 indication; >1.25M US patients, ~$3B US market.
- Cash $15.8M at June 30, 2026, down from $30.8M; funds operations through HCC readout into Q3 2027.
- Upcoming: KOL webinar Aug 19, 2026; TTI-101 HCC data 4Q 2026; UC trial start 2027 subject to IND/funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/0001104659-26-096417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-096417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer